Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KORU Medical SystemsKRMD -1.89%77 Return-on-Tangible-Equity is -19.82% as of Mar. 2026. GuruFocus rates KRMD with a GF Score™ of 77/100 and a GF Value™ of $4.09 (Fairly Valued). Among 759 Medical Devices & Instruments companies, KORU Medical Systems ranks worse than 69.04% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. KORU Medical Systems's annualized net income for the quarter that ended in Mar. 2026 was $-3.23 Mil. KORU Medical Systems's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $16.29 Mil. Therefore, KORU Medical Systems's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -19.82%.
The historical rank and industry rank for KORU Medical Systems's Return-on-Tangible-Equity or its related term are showing as below:
KRMD'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -54.81 Med: -10.51 Max: 12.5
Current: -14.28
During the past 13 years, KORU Medical Systems's highest Return-on-Tangible-Equity was 12.50%. The lowest was -54.81%. And the median was -10.51%.
KRMD's Return-on-Tangible-Equity is ranked worse than 69.04% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs KRMD: -14.28
KORU Medical Systems (NAS:KRMD) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
KORU Medical Systems Return-on-Tangible-Equity Related Terms
KORU Medical Systems Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for KORU Medical Systems's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KORU Medical Systems Return-on-Tangible-Equity Chart
KRMD vs EMBC, PDEX, SMTI: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KORU Medical Systems Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -19.82% mean?
KORU Medical Systems (KRMD) has a Return-on-Tangible-Equity of -19.82% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on KORU Medical Systems and its competitors. According to the industry distribution chart, KORU Medical Systems ranks #524 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 69%.
Is KORU Medical Systems' Return-on-Tangible-Equity too high?
KORU Medical Systems' current Return-on-Tangible-Equity is -19.82%. Based on the distribution chart, KORU Medical Systems ranks #524 out of 759 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, KORU Medical Systems has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' Return-on-Tangible-Equity compare to EMBC and PDEX?
According to the Medical Devices & Instruments industry distribution chart, KORU Medical Systems ranks #524 out of 759 companies for Return-on-Tangible-Equity. This places KORU Medical Systems in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on KORU Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KORU Medical Systems's current Return-on-Tangible-Equity is -19.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Fairly Valued. The stock's GF Value™ is $4.09, compared to a current price of $4.15 — trading 1.5% above its estimated fair value. The current Return-on-Tangible-Equity is -19.82%. KORU Medical Systems' overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current Return-on-Tangible-Equity is -19.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KORU Medical Systems (KRMD) Overvalued in 2026?
Based on GuruFocus' analysis, KORU Medical Systems stock appears to be overvalued.
The current stock price of $4.15 is trading 1.5% above its estimated GF Value™ of $4.09.
GuruFocus considers KORU Medical Systems to be Fairly Valued.
Key valuation signals for KRMD:
Return-on-Tangible-Equity: -19.82%
GF Value™: $4.09 vs. price of $4.15 (1.5% above fair value)
No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
77GF Score
Get the complete analysis for KRMD
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRMD has been successfully added to your 
